Want to see JP:4575 full AI Analyst Report?
Top Page
CanBas Co., Ltd.
(4575)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥780.00
▼(-0.89% Downside)
Action:Reiterated
Date:10/01/26
The score is primarily constrained by very weak financial performance (no revenue since FY2022, persistent losses, and sustained negative operating/free cash flow), partially mitigated by a debt-free balance sheet in recent years. Technicals are mixed but somewhat supportive with the price above key moving averages, while valuation remains unattractive/indeterminate due to a negative P/E and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt reduces solvency and interest-burden risk while giving CanBas more financial flexibility than during FY2021–FY2022, when leverage was materially higher. This provides a durable balance-sheet advantage as the company continues funding its development activities.
Negative Factors
No Recent Revenue
The absence of revenue since FY2022 indicates that CanBas has not yet established a recurring commercial business base. Without product sales, the company remains dependent on development progress and external funding, making financial performance highly sensitive to the timing and success of future commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt reduces solvency and interest-burden risk while giving CanBas more financial flexibility than during FY2021–FY2022, when leverage was materially higher. This provides a durable balance-sheet advantage as the company continues funding its development activities.
Read all positive factors
CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥13.94B
Dividend YieldN/A
Average Volume (3M)187.97K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth-8.52%
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-66.43
Shares Outstanding19,713,655
10 Day Avg. Volume67,160
30 Day Avg. Volume187,966
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)7.12
Price to Sales (P/S)0.00
P/FCF Ratio-8.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CanBas Co., Ltd. Business Overview & Revenue Model
Company Description
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating ...
CanBas Co., Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
14
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -820.00M | -984.00M | -671.00M | -608.00M |
| EBITDA | -1.36B | -1.16B | 53.65M | -1.24B | -848.65M |
| Net Income | -1.31B | -1.16B | -1.21B | -1.24B | -855.58M |
Balance Sheet | |||||
| Total Assets | 1.78B | 3.05B | 2.43B | 2.09B | 790.71M |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 2.83B | 1.89B | 1.62B | 737.77M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 367.34M |
| Total Liabilities | 134.71M | 107.00M | 91.99M | 153.85M | 540.02M |
| Stockholders Equity | 1.64B | 2.94B | 2.34B | 1.93B | 250.69M |
Cash Flow | |||||
| Free Cash Flow | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Operating Cash Flow | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Investing Cash Flow | 0.00 | 122.00K | 0.00 | 0.00 | 182.00K |
| Financing Cash Flow | 0.00 | 1.75B | 1.54B | 2.27B | 282.75M |
CanBas Co., Ltd. Technical Analysis
Positive
787.00
Price Trends
763.94
Positive
693.08
Positive
748.88
Positive
Market Momentum
-10.05
Positive
56.16
Neutral
34.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Positive. The current price of 787 is above the 20-day moving average (MA) of 767.80, above the 50-day MA of 763.94, and above the 200-day MA of 748.88, indicating a bullish trend. The MACD of -10.05 indicates Positive momentum. The RSI at 56.16 is Neutral, neither overbought nor oversold. The STOCH value of 34.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4575.
CanBas Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥13.94B | -11.71 | ― | ― | ― | -8.52% | |
47 Neutral | ¥37.14B | 58.87 | ― | ― | -47.32% | ― | |
46 Neutral | ¥33.99B | -80.54 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥14.24B | -30.50 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.57B | -7.56 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥10.41B | -5.66 | ― | ― | ― | 4.68% |
* Healthcare Sector Average
JP:4575
CanBas Co., Ltd.
792.00
-247.00
-23.77%
JP:4593
Healios KK
298.00
-201.00
-40.28%
JP:4599
StemRIM Inc.
170.00
-124.00
-42.18%
JP:4978
ReproCELL Inc.
142.00
-44.00
-23.66%
JP:7774
Japan Tissue Engineering Co., Ltd.
894.00
399.00
80.61%
JP:7776
CellSeed Inc.
224.00
-203.00
-47.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.